Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker - PubMed (original) (raw)
Comparative Study
. 2004 Jun;125(6):729-42.
doi: 10.1111/j.1365-2141.2004.04982.x.
Claire Mulligan, Jürgen Groet, Monica Spinelli, Andrea Rinaldi, Gareth Denyer, Afua Mensah, Simona Cavani, Chiara Baldo, Franca Dagna-Bricarelli, Ian Hann, Giuseppe Basso, Finbarr E Cotter, Dean Nizetic
Affiliations
- PMID: 15180862
- DOI: 10.1111/j.1365-2141.2004.04982.x
Comparative Study
Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker
Suzanne McElwaine et al. Br J Haematol. 2004 Jun.
Abstract
Transient myeloproliferative disorder (TMD) is a unique, spontaneously regressing neoplasia specific to Down's syndrome (DS), affecting up to 10% of DS neonates. In 20-30% of cases, it reoccurs as progressive acute megakaryoblastic leukaemia (AMKL) at 2-4 years of age. The TMD and AMKL blasts are morphologically and immuno-phenotypically identical, and have the same acquired mutations in GATA1. We performed transcript profiling of nine TMD patients comparing them with seven AMKL patients using Affymetrix HG-U133A microarrays. Similar overall transcript profiles were observed between the two conditions, which were only separable by supervised clustering. Taqman analysis on 10 TMD and 10 AMKL RNA samples verified the expression of selected differing genes, with statistical significance (P < 0.05) by Student's t-test. The Taqman differences were also reproduced on TMD and AMKL blasts sorted by a fluorescence-activated cell sorter. Among the significant differences, CDKN2C, the effector of GATA1-mediated cell cycle arrest, was increased in AMKL but not TMD, despite the similar level of GATA1. In contrast, MYCN (neuroblastoma-derived oncogene) was expressed in TMD at a significantly greater level than in AMKL. MYCN has not previously been described in leukaemogenesis. Finally, the tumour antigen PRAME was identified as a specific marker for AMKL blasts, with no expression in TMD. This study provides markers discriminating TMD from AMKL-M7 in DS. These markers have the potential as predictive, diagnostic and therapeutic targets. In addition, the study provides further clues into the pathomechanisms discerning self-regressive from the progressive phenotype.
Similar articles
- A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
Haemmerling S, Behnisch W, Doerks T, Korbel JO, Bork P, Moog U, Hentze S, Grasshoff U, Bonin M, Rieß O, Janssen JW, Jauch A, Bartram CR, Reinhardt D, Koch KA, Bandapalli OR, Kulozik AE. Haemmerling S, et al. Br J Haematol. 2012 Apr;157(2):180-7. doi: 10.1111/j.1365-2141.2012.09028.x. Epub 2012 Feb 1. Br J Haematol. 2012. PMID: 22296450 - Integrated differential transcriptome maps of Acute Megakaryoblastic Leukemia (AMKL) in children with or without Down Syndrome (DS).
Pelleri MC, Piovesan A, Caracausi M, Berardi AC, Vitale L, Strippoli P. Pelleri MC, et al. BMC Med Genomics. 2014 Dec 5;7:63. doi: 10.1186/s12920-014-0063-z. BMC Med Genomics. 2014. PMID: 25476127 Free PMC article. - Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
Roy A, Roberts I, Norton A, Vyas P. Roy A, et al. Br J Haematol. 2009 Oct;147(1):3-12. doi: 10.1111/j.1365-2141.2009.07789.x. Epub 2009 Jul 6. Br J Haematol. 2009. PMID: 19594743 Review. - Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
Vyas P, Roberts I. Vyas P, et al. Early Hum Dev. 2006 Dec;82(12):767-73. doi: 10.1016/j.earlhumdev.2006.09.016. Epub 2006 Oct 24. Early Hum Dev. 2006. PMID: 17064858 Review.
Cited by
- Immunophenotypic Analysis of Acute Megakaryoblastic Leukemia: A EuroFlow Study.
Brouwer N, Matarraz S, Nierkens S, Hofmans M, Nováková M, da Costa ES, Fernandez P, Bras AE, de Mello FV, Mejstrikova E, Philippé J, Grigore GE, Pedreira CE, van Dongen JJM, Orfao A, van der Velden VHJ, On Behalf Of The EuroFlow Consortium. Brouwer N, et al. Cancers (Basel). 2022 Mar 21;14(6):1583. doi: 10.3390/cancers14061583. Cancers (Basel). 2022. PMID: 35326734 Free PMC article. - Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.
Ge Y, Dombkowski AA, LaFiura KM, Tatman D, Yedidi RS, Stout ML, Buck SA, Massey G, Becton DL, Weinstein HJ, Ravindranath Y, Matherly LH, Taub JW. Ge Y, et al. Blood. 2006 Feb 15;107(4):1570-81. doi: 10.1182/blood-2005-06-2219. Epub 2005 Oct 25. Blood. 2006. PMID: 16249385 Free PMC article. - Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology.
Barwe SP, Sidhu I, Kolb EA, Gopalakrishnapillai A. Barwe SP, et al. Mol Ther Methods Clin Dev. 2020 Sep 16;19:201-209. doi: 10.1016/j.omtm.2020.09.007. eCollection 2020 Dec 11. Mol Ther Methods Clin Dev. 2020. PMID: 33102613 Free PMC article. - Hematopoietic disorders in Down syndrome.
Choi JK. Choi JK. Int J Clin Exp Pathol. 2008 Jan 1;1(5):387-95. Int J Clin Exp Pathol. 2008. PMID: 18787621 Free PMC article. - Down syndrome and leukemia: insights into leukemogenesis and translational targets.
Mateos MK, Barbaric D, Byatt SA, Sutton R, Marshall GM. Mateos MK, et al. Transl Pediatr. 2015 Apr;4(2):76-92. doi: 10.3978/j.issn.2224-4336.2015.03.03. Transl Pediatr. 2015. PMID: 26835364 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases